ArticleCurrent oncology (Toronto, Ont.)2026
Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study.
Daniel Rayson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.